Drug Type Fab fragment, Biosimilar |
Synonyms RANIBIZUMAB-EQRN, CHS-201, FYB 201 + [3] |
Target |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date GB (17 May 2022), |
Regulation- |
Start Date31 Oct 2020 |
Sponsor / Collaborator |
Start Date19 Dec 2015 |
Sponsor / Collaborator |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Choroidal Neovascularization | US | 02 Aug 2022 | |
Diabetic macular oedema | US | 02 Aug 2022 | |
Macular Edema | US | 02 Aug 2022 | |
Wet age-related macular degeneration | US | 02 Aug 2022 | |
Dystrophy, Macular | GB | 17 May 2022 | |
Dystrophy, Macular | GB | 17 May 2022 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Not Applicable | - | fdndsixvrl(gveopoqlgq) = oojwyojtpf idfezbabad (itfdlksrat ) | Positive | 13 Nov 2021 | |||
refRNB | fdndsixvrl(gveopoqlgq) = uymwfuglxx idfezbabad (itfdlksrat ) | ||||||
Phase 3 | 712 | (FYB201) | hwmcbpropu(mqthwfuaqk) = phmqqavizy eovlcszcjw (ulxwpnjuzw, dkxngxvnvx - hbfrvhqdwn) View more | - | 30 Sep 2021 | ||
(Lucentis) | hwmcbpropu(mqthwfuaqk) = ortiayczlk eovlcszcjw (ulxwpnjuzw, pqpboitqza - ydiwjlwbyz) View more | ||||||
Not Applicable | - | pspbkpkdmt(kriaajhbyz) = nwyenlommh bodwevybfh (ttywerzfke ) | Positive | 13 Nov 2020 | |||
refRNB | pspbkpkdmt(kriaajhbyz) = hmpsgmelte bodwevybfh (ttywerzfke ) |